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license (http://creativea noninvasive biomarker for Alzheimer’s disease (AD). We therefore measured retinal thickness in
well-characterized AD and control participants, considering ophthalmological confounders.
Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative
controls. All subjects underwent retinal thickness measurements with spectral domain optical
coherence tomography and an ophthalmological assessment to exclude ocular disease.
Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for
early- versus late-onset AD. We found significant associations between macular thickness and global
cortical atrophy [b 20.358; P 5 .01] and parietal cortical atrophy on magnetic resonance imaging
[b 20.371; P , .01] in AD cases.
Discussion: In this study, representing the largest optical coherence tomography cohort with
amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls,
despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal
thickness measurements as an AD biomarker.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Retinal thickness; Cortical atrophy; Alzheimer’s disease; Neurodegeneration; Biomarker1. Background
The development and use of Alzheimer’s disease (AD)
pathophysiological biomarkers have revolutionized both
AD diagnosis and research [1]. Specific biomarkers for neu-
rodegeneration, such as amyloid(-b) and (phosphorylated)
tau, support clinical diagnosis on the one hand and helpthor. Tel.: 131204440685; Fax: 131204448529.
enhaan1@vumc.nl
/j.dadm.2019.05.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).stratify patients for research purposes on the other [2].
Cross-sectional and longitudinal biomarker studies have
increased our insight into AD pathophysiology [3]. These
biomarkers are, however, invasive, expensive, or unsuitable
for repeated measurements, and noninvasive biomarkers are
thus urgently needed to increase understanding of patho-
physiology, improve diagnosis, and measure therapy effects.
The retina, an easily accessible part of the central nervous
system, might serve as such a noninvasive source of
biomarkers because it can be easily visualized with opticalimer’s Association. This is an open access article under the CC BY-NC-ND
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suggests retinal manifestations of AD that might be used
as biomarkers [4–6]. Retinal (layer) thinning measured
with optical coherence tomography (OCT) could be a
biomarker of neurodegeneration, reflecting cortical atrophy
[7], which might be the result of transsynaptic retrograde
neurodegeneration from affected cortices or from parallel
disease processes in the retina [8].
OCT studies in patients with AD performed to date have
presented conflicting findings [9–11]. Although several
studies showed mean peripapillary retinal nerve fiber layer
(pRNFL) thinning in AD [9–11], others showed changes
in single pRNFL sectors and others found no changes
[12–14]. In addition, some studies reported absence of
RNFL thinning, while thinning of total macular thickness
was present [9]. There are several possible reasons why
previously observed effects might be an overestimation of
true effects. In our recently published meta-analysis, we found
an indication of publication bias, with an overrepresentation of
positive studies [9]. In addition, it is worth noting that retinal
thickness is influenced by age [15] and ophthalmological
conditions, such as glaucoma [16], diabetes mellitus (DM)
(also without diabetic retinopathy)[17], and age-related
macular degeneration (AMD) [18], factors that were not al-
ways accounted for. Assessment of these confounders requires
ophthalmological screening, as a large proportion of patients
with glaucoma, diabetic retinopathy, andAMDare asymptom-
atic [19–21]. Because glaucoma, DM, and AMD are, like AD,
more prevalent with higher age and because associations
between AD, AMD, and glaucoma exist [22,23], retinal
changes could have been falsely attributed to AD in previous
studies. OCT studies using well-characterized cases that take
important confounders into account are thus needed to assess
the role of OCT as a diagnostic biomarker [9,24,25].
Furthermore, absence of retinal (layer) thinning in our pilot
study with early-onset AD (EOAD) cases [7], confirming an
earlier EOAD study [12], suggests that the retina might be
differently affected in EOAD compared with late-onset AD
(LOAD), indicating age of onset might be important in the
interpretation of findings.
The objective of the present study was threefold: (1) to
assess retinal thinning in well-phenotyped, amyloid-proven
AD cases compared with amyloid-negative controls, taking
effects of age and ophthalmological confounders into
account, (2) to assess relationships between retinal thickness
and established AD biomarkers, and (3) to assess retinal
thickness differences between LOAD and EOAD.2. Methods
2.1. Participants
We expanded our pilot cohort, as described earlier in
Alzheimer’s and Dementia: Diagnosis, Assessment &
Disease Monitoring [7]. In total, we enrolled 59 subjects
with AD (all Mini–Mental State Examination [MMSE]17, thus capable of giving informed consent) and 48
controls from the screening program of the Alzheimer
Center of the Amsterdam UMC (the Amsterdam Dementia
Cohort) [26]. Using 65 years of age as cutoff for EOAD
versus LOAD, 33 participants were defined as EOAD and
26 as LOAD. Patients and controls underwent a standardized
Amsterdam Dementia Cohort screening program including
(medical) history, MMSE, neuropsychological evaluation,
blood draw for apolipoprotein E (APOE) genotype,
magnetic resonance imaging (MRI), or computed
tomography scan if contraindications for MRI were present
[n5 2], and lumbar puncture. All patients fulfilled NIA-AA
criteria of AD and had evidence of amyloid pathology in
cerebrospinal fluid (CSF) and/or amyloid positron emission
tomography (amyloid-PET) [2]. In all cases with both CSF
and PET data available, biomarkers were concordant.
Controls were subjects with subjective cognitive decline,
defined as subjective cognitive complaints without objective
cognitive impairment on neuropsychological evaluation, no
signs of neurodegeneration on neuroimaging, and absence of
amyloid pathology based on CSF and/or amyloid-PET. In
addition, controls were enrolled through the EMIF-AD
PreclinAD twin study at our center (n 5 39) [27]. One
sibling of each monozygotic twin pair was selected to avoid
genetic dependency. Controls were eligible if neuropsycho-
logical evaluation and MRI were without abnormalities and
amyloid-PET showed absence of amyloid pathology.
Exclusion criteria for all participants were (ophthalmolo-
gical) conditions interfering with OCT quality and/or retinal
thickness such as severe cataract, age-related macular
degeneration and glaucoma, and neurological or systemic
chronic conditions known to interfere with retinal thickness
(i.e., multiple sclerosis, Parkinson’s disease [PD], and DM).
In addition, we excluded subjects with ischemic stroke and/or
mild-to-severe white-matter hyperintensities on MRI,
operationalized as a Fazekas score of .2 [28]. We excluded
one patient with EOAD who was later found to have a progra-
nulin mutation, a mutation known to directly affect retinal
integrity [29]. This subject was a significant outlier in our ana-
lyses. In addition, we excluded one control and one participant
with LOAD because of glaucoma and one control because of
bilateral epiretinal membrane (Supplementary Fig. 1).2.2. Ophthalmological assessment
Subjects underwent the following eye examinations to
exclude for ophthalmological pathology: best corrected
visual acuity, intraocular pressure using noncontact
tonometry (if intraocular pressure .20 mm Hg, contact
applanation tonometry was also performed), slit-lamp
examination of the anterior and posterior segment, fundus
photography (Topcon TRC 50DX type IA), Heidelberg
Retina Tomograph optic nerve head analysis, and frequency
doubling technology for visual fields. Tropicamide 0.5%
was administered for pupil dilation to facilitate optimal
ophthalmic examination. We followed the fourth European
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when two of the three following measurements were
abnormal: ocular pressure (.21 mm Hg), structural
glaucomatous changes of the optic nerve head (examined
with Heidelberg Retina Tomograph using the Moorfields
Regression Analysis), and functional changes in visual fields
(examined with frequency doubling technology [C20-1
screening]) [30]. All examinations were interpreted by an
experienced ophthalmologist (F.D.V.).
2.3. Spectral domain OCT imaging
We used Heidelberg Spectralis spectral domain OCT to
perform two protocols of each eye for each patient: (1) central
retina (macula) dense horizontal scanning; central 20! 20
area; 49 b-scans (averaging 15 frames per b-scan); 512 a-scans
per b-scan and (2) axonal ring scan around the optic nerve head
for RNFL (8 frames averaged). Peripapillary RNFL was
measured in six sectors provided by the Heidelberg software
(temporal superior, nasal superior, nasal, nasal inferior, tempo-
ral inferior, and temporal). Macular thickness was measured in
theEarly Treatment ofDiabetic Retinopathy Studymap (fovea
[Ø 1mm] and themean of four quadrants of both the inner ring
[Ø 1-3 mm], area 2 to 5, and the outer ring [Ø 3-6 mm], area 6
to 9) (Fig. 1). In the fovea, the inner and the outer ring
segmentation analysis was performed with the Heidelberg
segmentation software (version 1.9.204.0) to calculate
thickness of the following retinal layers: RNFL, ganglion
cell layer (GCL), and inner plexiform layer (IPL) (Fig. 1).
2.4. Magnetic resonance imaging
MRI visual rating scores were scored by a masked
experienced rater (F.B.) before the Amsterdam Dementia
Cohort multidisciplinary meeting, where a clinical diagnosisFig. 1. Overview of retinal imaging cohort. Overview of the retinal imaging co
tomography (OCT) imaging of the optic nerve head and macula and visual ratingwas made by consensus. Medial temporal lobe atrophy
(MTA), global cortical atrophy (GCA), parietal cortical
atrophy (PCA) [31–33], and Fazekas score [28] (for white
matter hyperintensities) were assessed.2.5. Cerebrospinal fluid analysis
CSF was analyzed using Innotest ELISA and
measured amyloid-b (1–42) (Ab1–42), tau-181 and
pTau. A tau-181/Ab1–42 ratio of 0.52 was considered
an AD profile [34].2.6. Amyloid-PET analysis
A subset of participants (n 5 88) was enrolled in
research programs that included amyloid-PET scanning
with the following tracers: 18F-florbetaben (NeuraCeq,
n 5 34), 18F-florbetapir (Amyvid, n 5 12), 18F-flutemeta-
mol (Vizamyl, n 5 39), and 11C-Pittsburgh compound B
(11C-PIB, n 5 3). Parametric images of amyloid-PET
scans were assessed by an experienced rater (B.N.v.B.)
and visually interpreted as amyloid positive or amyloid
negative by following the guidelines for individual
tracers.2.7. Data extraction
Mean pRNFL as well as in six sectors, total macular
thickness, and individual layer thickness in the Early
Treatment in Diabetes Retinopathy Study regions were
extracted. The mean of both eyes (if both eyes could be
examined) was calculated. The means of visual rating scores
were calculated for PCA and MTA scores.hort that included retinal thickness measurements using optical coherence
scores for cortical atrophy on magnetic resonance imaging (MRI).
Table 1
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Cohort characteristics
Demographics and
biomarkers
Alzheimer’s
disease Controls P value
Number 57 85
Sex (m/f) 32/25 42/43 .269*
Age, years 65.0 (67.6) 67.93 (69.4) .051y
MMSE 22 (17-28) 29 (25–30) .000y
APOE-ε4 genotypez, n (%)
ε4 homozygous 12 (22.2) 1 (1.3) .000*
ε4 heterozygous 24 (44.4) 18 (23.4) .009*
ε4 negative 18 (33.3) 58 (75.3) .000*
MRIx
Global cortical atrophy 1 (0-2) 0 (0-2) .001{
Medial temporal lobe
atrophy
1.5 (0-2.5) 0.25 (0-2.5) .000{
Parietal cortical atrophy 1 (0-3) 1 (0-2) .000{
CSF#, (ng/L)
Ab1–42 551.0 (6107.6) 1155.9 (6190.6) .000
{
Tau-181 717.8 (6337.4) 242.2 (684.7) .000
{
pTau 89.0 (629.6) 42.5 (611.6) .000{
Tau-181/Ab1-42 ratio 1.34 (6.0.8) 0.21 (60.1) .000
{
Ab-PET**
Positive/negative 23/0 0/64 .000*
Ophthalmological
Intra ocular pressure
(mmHg)
16.5 (62.3) 15.3 (62.7) .005y
Visual acuity (LogMAR) 20.00 (6.07) 20.02 (6.12) .191y
Significant results in bold.
Abbreviations: Ab, amyloid b; AD, Alzheimer’s disease; APOE,
apolipoprotein; CSF, cerebrospinal fluid; MRI, magnetic resonance
imaging; PET, positron emission tomography.
*c2 test.
yIndependent-samples t-test.2.8.1. Power calculation
Based on our previous meta-analysis, selecting spectral
domain OCT scanners in 553 AD cases compared with
486 controls [9], pRNFL thinning of approximately 7 mm
can be expected. Assuming a true effect of 7 mm and a
standard deviation of 8 mm, 21 subjects in each group are
needed to reject the null hypothesis of no difference between
the disease and control group with a power of 0.80. In
addition, a total macular thickness decrease of
approximately 14 mm can be expected. Assuming a true
effect of 14 mm and a standard deviation of 615 mm, 18
subjects in each group are needed to reject the null
hypothesis of no difference between the disease and control
group with a power of 0.80.
2.8.2. Data analysis
Data were visually tested for a normal distribution using
histograms and Q-Q plots. Measures that were normally
distributed were tested with an independent t-test,
non-normally distributed measures with a Mann-Whitney
U test, and binary variables with a c2 test. Linear regression
models were used to assess if changes in retinal (layer)
thickness were attributable to diagnosis, corrected for age
and sex. All b’s reported are standardized b’s. Bonferroni
correctionwas used to correct for multiple testing. Data anal-
ysis was performed with IBM SPSS Statistics (version 22.0).
GraphPad Prism (version 6.0) was used to generate graphs.zAPOE-ε4 genotype was available in 54 AD cases and 77 controls.
xMRI was available in 54 AD cases and 80 controls.
{Mann-Whitney U test.
#CSF was available in 54 AD cases and 36 controls.
**Amyloid-PET was available in 23 AD cases and 64 controls.3. Results
We included 57 AD cases (32 EOAD, 25 LOAD) and 85
controls (Table 1, Fig. 1) of which 15 EOAD cases and 15
controls were described in our previous pilot study [7]. We
found no significant differences in age, sex, and visual
acuity. Intraocular pressure showed a statistically significant
difference within the normal limits between groups (AD:
16.5 mmHg [62.3], controls: 15.3 mmHg [62.7],
P , .01). By design, MMSE, atrophy scores on MRI, CSF
biomarkers, and amyloid-PET were indicative of an AD
diagnosis in AD cases and normal in controls (Table 1). As
expected, APOE-ε4 genotype was more prevalent in AD
cases (66.6% in AD vs. 24.7% in controls), whereas controls
were more often APOE-ε4 negative (33.3% in AD vs. 75.3%
in controls, both P , .01) [35].
3.1. Peripapillary RNFL does not discriminate AD from
controls
Values of mean pRNFL and in the 6 different sectors
(temporal, temporal superior, nasal superior, nasal, nasal
inferior, and temporal inferior) showed overlap between
AD cases and controls as indicated in a TSNIT plot in
Fig. 2. Mean pRNFL was 94.5 mm (68.7) for AD and
96.0 mm (610.3) for control participants, with standarddeviations exceeding the expected effect size (7 mm).
Despite trends of thinning in mean, temporal, temporal
superior, and nasal inferior RNFL in AD cases, linear
regression models assessing relationships between RNFL
and diagnosis, adjusted for age and sex, showed no
significant disease effect. Temporal inferior RNFL showed
a thinning of 8.7 mm [b 20.222, P 5 .007], just above the
significance level after Bonferroni correction (P 5 .006).
Additional analysis stratified for EOAD and LOAD versus
controls showed no significant disease effect
(Supplementary Table 1). We found no significant
correlation between mean pRNFL thickness and MMSE
adjusting for age and sex [b 0.147, P 5 .078] in the total
cohort, nor stratified for diagnosis (AD: [b 0.063,
P 5 .629]; controls: [b 0.017, P 5 .880]).3.2. Total and individual macular layer thickness does not
discriminate AD from controls
Total retinal thickness and individual layer thickness of
RNFL, GCL, and IPL in the inner ring and the outer ring
Fig. 2. Peripapillary retinal nerve fiber layer thickness (pRNFL) in patients
with Alzheimer’s disease (AD) and controls; pRNFL thickness in mm
(means, 95% CI) in patients with AD (n 5 57, red) and controls (n 5 85,
blue) in a TSNIT plot, showing pRNFL thickness in different sectors
(temporal, temporal superior, nasal superior, nasal, nasal inferior, temporal
inferior, and temporal). Mean pRNFL is shown in dashed lines.
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did similarly not discriminate AD cases from controls
(Table 2). Despite trends of thinning in AD cases, linear
regression models assessing relationships between macular
(layer) thickness and diagnosis, adjusted for age and sex,
showed no significant disease effect (Table 2). In the same
models, total retinal thickness, GCL, and IPL in the inner
and outer ring were inversely correlated with age (b’s
between 20.200 and 20.400, all P , .01). Additional
analysis stratified for EOAD and LOAD versus controls
yielded similar results (Supplementary Table 1). We found
no significant correlation between total retinal thickness
(mean inner and outer ring) and MMSE adjusted for age
and sex [b 0.078, P 5 .354], nor for the retinal thickness
in the inner ring [b 0.065, P 5 .440] and the outer ring
[b 0.083, P 5 .321], respectively.
3.3. Macular thickness correlates with visual rating scores
for GCA and PCA scores
Next, we assessed relationships between retinal measures
and AD biomarkers: visual rating scores on MRI (GCA,
PCA, MTA, and Fazekas) and CSF biomarkers (Ab1-42,
Tau-181, pTau, and Tau-181/Ab1-42 ratio). We found
significant inverse associations between perifoveal macular
thickness and GCA [b 20.329, P 5 .002] and PCA [b
20.363 P5 .001] scores in the total cohort, after correction
for multiple testing using Bonferroni correction. Stratifying
for diagnosis, this effect was found to be attributable to AD
cases (GCA [b 20.358, P 5 .010] and PCA [b 20.371,
P 5 .007]). In controls, perifoveal macular thickness did
not correlate with GCA (b 20.205, P 5 .188) or PCA
(b 20.088 P 5 .556). We found no associations betweenpRNFL thickness and visual rating scores for atrophy on
MRI and between pRNFL or macular thickness and any of
CSF biomarkers in the total group (Table 3), nor within
the total AD patient group (data not shown). In addition,
no associations between pRNFL or macular thickness and
white matter hyperintensities (Fazekas score) were found.3.4. Retinal measures do not differentiate different APOE
genotypes
Finally, we assessed retinal measures stratified for APOE
genotype independent of diagnosis; both dichotomous
between APOE-ε4 carriers and noncarriers and between
APOE-ε4 homozygotes, heterozygotes, and noncarriers.
Retinal measures showed no significant differences between
different APOE genotypes.4. Discussion
In this study that represents the largest OCT cohort of
well-characterized, amyloid-proven cases of EOAD and
LOAD thus far, we show that retinal (layer) thickness does
not discriminate AD cases from controls, despite
unequivocal changes on clinical, neuroimaging, CSF, and
PET measures. Importantly, by using a thorough baseline
ophthalmological screening, we were able to exclude
confounding from DM, glaucoma, and AMD and measure
direct downstream effects of pure AD pathology on retinal
structure in AD cases. These results confirm earlier analyses
in our pilot cohort [7] and a recent report in a large cohort of
AD and mild cognitive impairment participants [14], while
contradicting others [9,11]. Taken together, our results do
not support the notion that retinal thickness measurements
with OCT can currently serve as a diagnostic biomarker
for AD.
Adding to the existing literature, we complemented
measurements of pRNFL and total macular thickness with
individual layer segmentation of the macula, to assess
changes in the RNFL, GCL, and IPL, layers preferentially
believed to be involved in AD [36]. Confirming findings
from our previous pilot cohort, we did not observe
significant differences in inner retinal layer thickness
between AD cases and controls, whereas known associations
between age and macular GCL and IPL [15] were observed.
We did observe trends of retinal (layer) thinning in AD cases
that possibly indicate subtle changes in the retina, implying
that the effect size of structural changes in the retina might
be smaller than in the brain. As we were powered to detect
differences of 66 mm in pRNFL thickness and 68 mm of
total retinal thickness, we doubt that these (or smaller
differences) are of clinical relevance given the individual
variation of these measures in our cohort and the general
population. Given contradictory findings in literature
whether retinal (layer) thinning is present and could function
as a biomarker in AD, a meta-analysis based on individual
data may be a step forward to answer this question. It could
Table 2
Macular (layer) thickness in ETDRS regions in AD and control participants
Linear regression
AD Age Sex
Retinal thickness measure Alzheimer’s disease (AD) Controls b P value b P value b P value
Total retinal thickness (mm)
Inner ring 338.43 (616.67) 341.73 (613.76) 20.148 .080 20.207 .015 0.082 .327
Outer ring 292.38 (613.12) 295.17 (612.30) 20.143 .086 20.257 .002 20.114 .166
Retinal nerve fiber layer (mm)
Inner ring 21.69 (61.90) 21.88 (61.86) 20.056 .515 0.008 .925 0.111 .195
Outer ring 34.57 (63.42) 35.96 (64.35) 20.160 .053 20.055 .505 20.263 .002
Ganglion cell layer (mm)
Inner ring 49.71 (64.66) 50.15 (64.58) 20.110 .170 20.382 ,.001 0.005 .948
Outer ring 33.96 (63.17) 34.17 (63.13) 20.098 .212 20.423 ,.001 20.053 .495
Inner plexiform layer (mm)
Inner ring 41.22 (63.11) 41.33 (62.98) 20.089 .259 20.405 ,.001 0.073 .351
Outer ring 28.35 (62.53) 28.33 (62.12) 20.051 .530 20.347 ,.001 20.020 .808
NOTE. Total retinal thickness, retinal nerve fiber layer thickness, ganglion cell layer thickness, and inner plexiform layer thickness in the fovea, inner ring
(Ø 1-3 mm around the fovea) and outer ring (Ø 3–6 mm around the fovea) of the Early Treatment in Diabetes Retinopathy Study (ETDRS) grid in AD (n5 57)
and controls (n5 85). Means (6SD), standardized b’s, and uncorrected P values of linear regression models with retinal measures as dependent variables and
diagnosis, age, and sex (male5 1, female5 0) as independent variables are shown. Significant findings after Bonferroni correction (0.05/85 0.006) are shown
in bold.
Table 3
Relationships between retinal measures and MRI visual rating scores and
CSF biomarkers in the total cohort
A) Magnetic resonance imaging GCA PCA MTA Fazekas
Mean pRNFL
b 0.001 0.037 20.111 0.001
P value 0.992 0.701 0.231 0.995
Perifoveal macular thickness
b 20.314 20.276 20.204 20.108
P value 0.001 0.003 0.028 0.298
B) Cerebrospinal fluid analysis Ab1-42 Tau-181 pTau Tau/Ab
Mean pRNFL
b 0.025 20.028 0.013 0.027
P value 0.811 0.790 0.903 0.795
Perifoveal macular thickness
b 0.142 0.047 0.112 0.033
P value 0.178 0.660 0.296 0.756
NOTE. Linear regression models assessing relationships between mean
pRNFL and perifoveal macular thickness (inner 1 outer ring) with visual
rating scores on MRI (GCA, PCA, MTA, and Fazekas) and CSF biomarkers
(Ab1–42, Tau-181, pTau, and Tau/Ab ratio) adjusted for age and sex
(male5 1, female5 0) in the total cohort. Standardized b’s and uncorrected
P values are shown. Significant findings after Bonferroni correction
(0.05/8 5 0.006) are shown in bold. MRI subgroup (n 5 134) and CSF
subgroup (n 5 90).
Abbreviations: GCA, global cortical atrophy;MTA,medial temporal lobe
atrophy; PCA, parietal cortical atrophy; pRNFL, peripapillary retinal nerve
fiber layer; Ab, amyloid b; AD, Alzheimer’s disease; CSF, cerebrospinal
fluid; MRI, magnetic resonance imaging; PET, positron emission
tomography.
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future longitudinal OCT measurements might be more sen-
sitive to subtle changes and could eliminate interindividual
differences. A recent study in preclinical AD shows that lon-
gitudinal measurements might be sensitive to macular RNFL
thinning over time [37]. These studies should ideally also
include axial length measurements as this could contribute
to interindividual differences and was not accounted for in
this study.
By using well-characterized cases and controls, we were
able to assess patients confirmed by AD biomarkers in CSF
and associate retinal measures with visual rating scores on
MRI, CSF biomarkers, and MMSE [2]. We found a signifi-
cant relationship between total retinal thickness in the mac-
ula and measures of neurodegeneration on MRI (GCA and
PCA scores) in the total cohort. Interestingly, stratified for
diagnosis, these associations were selective for AD, possibly
reflecting a selective pathological process in AD cases that
involves both the cerebral cortex and the macula. Alterna-
tively, an absence of associations in controls may be the
result of a relatively low variance of atrophy scores in con-
trols. In contrast, no relationships between cortical thickness
and pRNFL thickness were found. This finding could be a
reflection of relationships between cortical thickness and
cell bodies of the macula that reflect gray matter, and not
with axons in the pRNFL that reflect white matter. Alterna-
tively, it could represent a statistical phenomenon, with less
spread and variability in pRNFL thickness. In a previous
study, relationships between macular and pRNFL thickness
andMTAwere reported in a study of cognitively normal con-
trols [38], whereas others described relationships between
gray matter volume and retinal layer thickness in controls
but not in cognitively impaired cases [39]. Further research
is needed to elucidate relationships between brain and retinain AD and controls and could possibly be complemented
with cortical thickness and subcortical volume analyses. In
line with findings from our pilot cohort, we found no associ-
ations between pRNFL and macular thickness and CSF bio-
markers or MMSE as measure for disease severity [7].
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thinning might be differently involved in EOAD versus
LOAD. Previous studies showed differences in cortical
atrophy patterns on MRI between EOAD and LOAD,
showing a diffuse atrophy pattern with a posterior gradient
(posterior cingulate and temporal-parietal cortex and
precuneus) or relative absence of atrophy in EOAD and
predominant MTA in LOAD [40–42]. Both adjusted and
unadjusted for age, sex, and ophthalmological
confounders, we did not observe significant differences in
retinal thickness between LOAD and EOAD participants.
It’s debatable whether 65 or 70 years of age should be
used as cutoff for EOAD versus LOAD [43,44]. We
therefore performed additional analyses using 70 years as
cutoff (EOAD n 5 44, LOAD n 5 13, controls n 5 85)
that yielded similar results.
As retinal (layer) thickness is influenced by multiple
variables other than neurodegenerative disease, including
AMD, glaucoma, age, DM, and systemic conditions, we
foresee that more specific pathological biomarkers in the
retina hold more promise as AD biomarkers. Although the
presence of retinal tau, Ab, and neuroinflammation is still
controversial, these might be promising molecular
biomarkers for diagnosis and possible endpoints in clinical
trials [45–48]. With molecular imaging on the horizon in
ophthalmology, optical techniques might enable us to
detect such specific retinal changes in the future [49,50].5. Conclusion
Retinal thickness does not differ between amyloid-
proven AD cases and amyloid-negative controls in a
well-characterized sample of patients, taking confounding
factors into account. Future studies should focus on
longitudinal measurements of retinal layer thickness and
specific molecular biomarkers such as amyloid, tau, and
neuroinflammation.Acknowledgments
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1. Systematic review: The authors searched PubMed
for all publications assessing retinal thinning in Alz-
heimer’s disease (AD). Well-phenotyped cohorts
including amyloid status, visual rating scores on
magnetic resonance imaging, and ophthalmological
screening have not previously been examined.
2. Interpretation: In this study, representing the largest
OCT cohort with amyloid-proven AD cases, we
show that retinal thickness does not discriminate
patients with AD from controls, despite evident
changes on clinical, neuroimaging, and CSF mea-
sures, querying the use of retinal thickness mea-
surements as an AD biomarker.
3. Future directions: Future studies, including longitu-
dinal measurements of retinal layer thickness and
specific molecular biomarkers such as amyloid, tau,
and neuroinflammation, are needed to assess the
retina as a potential source of noninvasive AD bio-
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